Advertisement

Les traitements antiangiogéniques modifient-ils ďhistoire naturelle de la maladie en phase métastasique?

  • Damien Pouessel
  • Stéphane Culine
Chapter
  • 330 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

La constatation historique du caractère hypervascularisé des cancers du rein à cellules claires suggérait ľexistence ďune importante prolifération vasculaire. Ľacquisition ultérieure des connaissances concernant les mécanismes moléculaires impliqués dans la carcinogenèse rénale a confirmé le rôle particulièrement important de ľangiogenèse dans le développement tumoral rénal. La preuve du concept a été récemment apportée par la démonstration ďun bénéfice clinique en situation métastatique lors de ľutilisation de molécules ciblant les effecteurs de ľangiogenèse. Dans ce chapitre, nous rappellerons les bases physiopathologiques de ľangiogenèse tumorale et les mécanismes ďaction des molécules antiangiogéniques, puis nous développerons les résultats des essais cliniques ayant permis de valider ľutilisation de ces molécules dans la pratique quotidienne.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Escudier B, Eisen T, Stadler WM et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–34PubMedCrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Hutson TE, Tomczak P et al. (2007) Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–24PubMedCrossRefGoogle Scholar
  3. 3.
    Hudes G, Carducci M, Tomczak P et al. (2007) Temsirolimus interferon-alfa or both for advanced renal cell carcinoma. N Engl J Med 356: 2271–81PubMedCrossRefGoogle Scholar
  4. 4.
    Hicklin DJ, Ellis LM (2005) Role of the Vascular Endothelial Growth Factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011–27PubMedCrossRefGoogle Scholar
  5. 5.
    Olsson AK, Dimberg A, Kreuger J et al. (2006) VEGF receptor signalling — in control of vascular function. Nat Rev Mol Cell Biol 7: 359–71PubMedCrossRefGoogle Scholar
  6. 6.
    Folkman J (1992) The role of angiogenesis in tumour growth. Semin Cancer Biol 3: 65–71PubMedGoogle Scholar
  7. 7.
    Patard JJ, Rioux-Leclercq N, Fergelot P (2006) Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49: 633–43PubMedCrossRefGoogle Scholar
  8. 8.
    Hudson CC, Liu M, Chiang GG et al. (2002) Regulation of hypoxia-inductible factor-1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004–14PubMedCrossRefGoogle Scholar
  9. 9.
    Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 288: 1779–802CrossRefGoogle Scholar
  10. 10.
    Wilhelm S, Carter C, Lynch M et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835–44PubMedCrossRefGoogle Scholar
  11. 11.
    Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 27: 884–96CrossRefGoogle Scholar
  12. 12.
    Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–88PubMedCrossRefGoogle Scholar
  13. 13.
    Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–34PubMedCrossRefGoogle Scholar
  14. 14.
    Ratain MJ, Eisen T, Stadler WM et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–12PubMedCrossRefGoogle Scholar
  15. 15.
    Escudier B, Eisen T, Stadler WM et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–34PubMedCrossRefGoogle Scholar
  16. 16.
    Bukowski RM, Eisen T, Szczylik C et al. (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Proc Am Soc Clin Oncol 18S: 240s (abstract 5023)Google Scholar
  17. 17.
    Atkins MB, Hidalgo M, Stadler WM et al. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–18PubMedCrossRefGoogle Scholar
  18. 18.
    Motzer RJ, Mazumdar M, Bacik J et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530–40PubMedGoogle Scholar
  19. 19.
    Escudier B, Koralewski P, Pluzanska A et al. (2007) A randomized, controlled, doubleblind phase III study (AVOREN) of bevacizumab/interferon-α 2a vs placebo/interferon-α 2a as first-line therapy in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 18S: 2s (abstract 3)Google Scholar
  20. 20.
    Szczylik C, Demkow T, Staehler M et al. (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Proc Am Soc Clin Oncol 18S: 241s, (abstract 5025)Google Scholar
  21. 21.
    Motzer RJ, Hutson TE, Tomczak P et al. (2007) Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–24PubMedCrossRefGoogle Scholar
  22. 22.
    Motzer RJ, Figlin RA, Hutson TE et al. (2007) Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognosis factors. Proc Am Soc Clin Oncol 18S: 241s (abstract 5024)Google Scholar
  23. 23.
    Hudes G, Carducci M, Tomczak P et al. (2007) Temsirolimus, interferon-alfa or both for advanced renal cell carcinoma. N Engl J Med 356: 2271–81PubMedCrossRefGoogle Scholar
  24. 24.
    Parasuraman S, Hudes G, Levy D et al. (2007) Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR. Proc Am Soc Clin Oncol 18S: 247s (Abstract 5049)Google Scholar
  25. 25.
    Choueiri TK, Garcia JA, Elson P et al. (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543–550PubMedCrossRefGoogle Scholar
  26. 26.
    Sablin MP, Bouaita L, Balleyguier C et al. (2007) Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc Am Soc Clin Oncol 18S: 244s (Abstract 5038)Google Scholar
  27. 27.
    Dham A and Dudek AZ (2007) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc Am Soc Clin Oncol 18S: 261s (Abstract 5106)Google Scholar
  28. 28.
    Amato RJ, Harris P, Dalton M et al. (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 18S: 241s (Abstract 5026)Google Scholar
  29. 28.
    Houk BE, Bello CL, Michaelson MD et al. (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma: A population pharmacokinetic/pharmacodynamic approach. Proc Am Soc Clin Oncol 18S: 241s (Abstract 5027)Google Scholar
  30. 29.
    Plantade A, Choueiri T, Escudier B et al. (2007) Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma patients treated with tyrosine-kinase inhibitors sunitinib and sorafenib. Proc Am Soc Clin Oncol 18S: 244s (Abstract 5037)Google Scholar
  31. 30.
    Dutcher JP, Szczylik C, Tannir N et al. (2007) Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Proc Am Soc Clin Oncol 18S: 243s (Abstract 5033)Google Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Damien Pouessel
    • 1
  • Stéphane Culine
    • 1
  1. 1.Département ďoncologie médicaleCentre régional de lutte contre le cancer Val ďAurelleMontpellier cedex

Personalised recommendations